Exin Therapeutics Is Using AI to Crack the Brain's Hardest Drug Targets
Neurological drug development has a 90% failure rate. Exin Therapeutics thinks multimodal AI and high-throughput mouse studies can change those odds.
Neurological drug development has a 90% failure rate. Exin Therapeutics thinks multimodal AI and high-throughput mouse studies can change those odds.
AI agents are shipping to production faster than teams can debug them. Subtrace traces every HTTP request and tool call without touching your code, giving you a real-time window into what your agents are doing and why they fail.